Barry Rosenstein's Jana Partners has teamed up with former Bulgari boss Francesco Trapani to nab a stake and three board seats. » Read More
A U.S. appeals court upheld a dismissal, saying hedge funds can't sue over investments in Fannie and Freddie. » Read More
By: Bob Pisani
Buybacks keep rolling along, but here is why they are no panacea for all of the market's problems. » Read More
By: Tae Kim
Bloomin' Brands closed 43 stores on Feb. 15, according to the company. » Read More
Protectionist policies by President-elect Donald Trump could result in jobs losses, as companies use machines instead of human labor.
Investors are putting too much pressure on Goldman Sachs to carry the Dow to 20,000, CNBC's Jim Cramer said on Monday.
Ariad Pharmaceuticals investors are having a good day.
China has quietly ushered in a series of new measures aimed at better managing the value of its currency, the yuan.
There's a good chance that most companies will not be doing any dramatic fist pumps about earnings in the new year.
Lee believes the first half will see the market slide from its current record perch, then rally just enough to get back to unchanged.
The biggest risk to the rally may turn out to be something the new administration can't do anything about, El-Erian tells CNBC.
Fewer than 1 in 5 large-cap active managers — 19 percent — produced returns that beat the Russell 1000 market index, according to BofAML.
BlackRock is encouraging investors to start looking at opportunities in Europe, even though geopolitical stability is in question.
Jim Cramer previewed how the upcoming JPMorgan healthcare conference could impact the industry.
The "Fast Money" traders weighed which stocks to buy as the Dow Jones industrial average neared 20,000 on Friday.
Traders are looking for more details on the Trump agenda in the week ahead, and that could help steer the "Trump trade."
Jim Cramer pins the success of stocks since Election Day on the smart moves of this CEO.
Let the beer wars begin! Jim Cramer compares Constellation Brands to Molson Coors and crowns one the king of beer.
Jim Cramer expects bank and drug stocks to be on the red-hot griddle.
Pro-growth policy announcements are part of the reason for the rally, now they need to be implemented, Allianz's Mohamed El-Erian says.
CEO Stack said 2016 was a year of solid execution for the company that set the stage for continued growth of its pain-relief drug, Exparel.
Optimism will spur the market higher this year, but there may be a correction ahead, Wells Capital Management's Jim Paulsen says.
Fiat Chrysler saw its U.S.-listed shares spike more than 6 percent on Friday, boosted by an upgrade at Goldman Sachs.
US District Judge Sue Robinson banned the marketing, selling or manufacturing of Regeneron's cholesterol-lowering drug, Praluent.
Get the best of CNBC in your inbox